Show simple item record

dc.contributor.authorIlmi, Rashiden
dc.contributor.authorTseriotou, Elenien
dc.contributor.authorStylianou, Panayiotaen
dc.contributor.authorChristou, Yiota A.en
dc.contributor.authorTtofi, Iakoviaen
dc.contributor.authorDietis, Nikolasen
dc.contributor.authorPitris, Costasen
dc.contributor.authorOdysseos, Andreani D.en
dc.contributor.authorGeorgiades, Savvas N.en
dc.creatorIlmi, Rashiden
dc.creatorTseriotou, Elenien
dc.creatorStylianou, Panayiotaen
dc.creatorChristou, Yiota A.en
dc.creatorTtofi, Iakoviaen
dc.creatorDietis, Nikolasen
dc.creatorPitris, Costasen
dc.creatorOdysseos, Andreani D.en
dc.creatorGeorgiades, Savvas N.en
dc.description.abstractThe epidermal growth factor receptor (EGFR) is a key target in anticancer research, whose aberrant function in malignancies has been linked to severe irregularities in critical cellular processes, including cell cycle progression, proliferation, differentiation, and survival. EGFR mutant variants, either transmembrane or translocated to the mitochondria and/or the nucleus, often exhibit resistance to EGFR inhibitors. The ability to noninvasively image and quantify EGFR provides novel approaches in the detection, monitoring, and treatment of EGFR-related malignancies. The current study aimed to deliver a new theranostic agent that combines fluorescence imaging properties with EGFR inhibition. This was achieved via conjugation of an in-house-developed ((4-bromophenyl)amino)quinazoline inhibitor of mutant EGFR-TK, selected from a focused aminoquinazoline library, with a [Ru(bipyridine)3]2+ fluorophore. A triethyleneglycol-derived diamino linker featuring (+)-ionizable sites was employed to link the two functional moieties, affording two unprecedented Ru conjugates with 1:1 and 2:1 stoichiometry of aminoquinazoline to the Ru complex (mono-quinazoline-Ru-conjugate and bis-quinazoline-Ru-conjugate, respectively). The bis-quinazoline-Ru-conjugate, which retains an essential inhibitory activity, was found by fluorescence imaging to be effectively uptaken by Uppsala 87 malignant glioma (grade IV malignant glioma) cells. The fluorescence imaging study and a time-resolved fluorescence resonance energy transfer study indicated a specific subcellular distribution of the conjugate that coincides with that of a mitochondria-targeted dye, suggesting mitochondrial localization of the conjugate and potential association with mitochondria-translocated forms of EGFR. Mitochondrial localization was further documented by the specific concentration of the bis-quinazoline-Ru-conjugate in a mitochondrial isolation assay.en
dc.sourceMolecular Pharmaceuticsen
dc.titleA Novel Conjugate of Bis[((4-bromophenyl)amino)quinazoline], a EGFR-TK Ligand, with a Fluorescent Ru(II)-Bipyridine Complex Exhibits Specific Subcellular Localization in Mitochondriaen
dc.description.endingpage4273Πολυτεχνική Σχολή / Faculty of EngineeringΤμήμα Ηλεκτρολόγων Μηχανικών και Μηχανικών Υπολογιστών / Department of Electrical and Computer Engineering
dc.source.abbreviationMol. Pharm.en
dc.contributor.orcidGeorgiades, Savvas N. [0000-0002-6106-9904]
dc.contributor.orcidPitris, Costas [0000-0002-5559-1050]
dc.contributor.orcidDietis, Nikolas [0000-0002-8365-3837]

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record